From:	Martyres,Dr.,Domnic (PAT) BII-DE-B
To:	zrBIB BDM-resultsdisclosure
Cc:	zrBIB BDM-resultsdisclosure; zxBIB Martins,Tatiana (MED BDS) EXTERNAL
Subject:	Re: 1199-0449: Final Rule – CTP/NIS protocol & TSAP/SEAP for publication on clinicaltrials.gov
Date:	Tuesday, February 25, 2025 7:45:06 PM
Attachments:	image001.png Image.png

Dear Tatiana,
I confirm there are no further redactions required from patents' perspective.
Regards,
Domnic

Dr. Domnic Martyres (He/him)
Attorney/Group Head, HP Patents NCE I&R

Boehringer Ingelheim International GmbH
Birkendorfer Str. 65 | 88397 Biberach

T +49 (7351) 54-3140
E domnic.martyres@boehringer-ingelheim.com

Life forward

From: zxBIB Martins,Tatiana (MED BDS) EXTERNAL <tatiana.martins.ext@boehringer-ingelheim.com> on behalf of zrBIB BDM-resultsdisclosure <BDM-resultsdisclosure.bib@boehringer-ingelheim.com>
Sent: Tuesday, February 18, 2025 6:05:48 PM
To: Martyres,Dr.,Domnic (PAT) BII-DE-B <domnic.martyres@boehringer-ingelheim.com>
Cc: zrBIB BDM-resultsdisclosure <BDM-resultsdisclosure.bib@boehringer-ingelheim.com>; zxBIB Martins,Tatiana (MED BDS) EXTERNAL <tatiana.martins.ext@boehringer-ingelheim.com>
Subject: 1199-0449: Final Rule – CTP/NIS protocol & TSAP/SEAP for publication on clinicaltrials.gov

Dear Domnic,

In accordance with the Study Disclosure and Data and Document Sharing SOP, redacted version of CTP&SEAP have to be provided for publication on clinicaltrials.gov.

The pre-redaction of CTP & SEAP of trial 1199-0449 has been performed, please find the documents attached.

Please review the pre-redacted documents for additional items to be redacted. Also please check whether any pre-redacted items should not be redacted. Additional instructions are available in the following HTG: Preparing CTPs/ONIS protocols and TSAPs/SEAPs for posting on ClinicalTrials.gov – a process description. Please note that the trial team has already reviewed the documents and any comments they had can be found in the attached documents.

If you identify any additional items, please highlight these in the pdf file, include a rationale for the redaction by using the Adobe commenting function, and send the **final document** with the

comments back to me by 25-Feb-25. If there are no additional items identified, please also let me know.

Thank you very much and if you have any questions, please feel free to contact me.

Kind regards,
Tatiana

Tatiana Martins
Global Biostatistics & Data Sciences

Beauftragt durch / On behalf of Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Str. 65 | 88397 Biberach

E tatiana.martins.ext@boehringer-ingelheim.com

Life forward